AKT1 and neoplasm: In addition to inhibiting activation of the insulin-dependent PI3K/Akt/mTOR pathway, several studies have shown that metformin inhibits mTOR activation through activation of AMPK, which is also a critical mechanism of metformin in exerting its anti-tumor effects [26, 27].